Takeda today announced the launch of a new expert Report on COPD, introduced at a Takeda organised press conference on the occasion of the 2012 European Respiratory Society (ERS) Annual Congress taking place from 1- 5 September in Vienna, Austria.
The Report, entitled ‘The Shifting Paradigm in Chronic Obstructive Pulmonary Disease (COPD) Management,’ was initiated and developed by Takeda Pharmaceuticals International GmbH and is a compilation of opinion articles from a panel of key international respiratory experts, the European Federation of Allergy and Airways Diseases Patients’ Association (EFA) and COPD patients, reflecting updated guidance and research. The new expert Report was developed in response to a recent shift in emphasis in COPD management which now places future risk at equal importance to treatment of current disability. Treatment objectives are now divided into two groups: reducing symptoms and reducing risk.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56582-expert-report-on-copd-launch
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced its new WebMD Pain Coach™ for iPhone, a unique free mobile application for consumers and patients living with chronic pain. As the leader in mobile health, WebMD provides trusted health information anytime and anywhere with its mobile web and applications for consumers and physicians. The new WebMD Pain Coach™ app builds on WebMD’s market-leading mobile applications through a holistic approach that helps users create a balanced lifestyle.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57975-webmd-launches-unique-new-mobile-app-for-those-living-with-chronic-pain
Nearly 7.5 million students (K – 12th grade) are chronically absent every school year – missing enough school to put them at severe risk of dropping out or failing to graduate. Chronic absenteeism, which is defined as missing at least 10 percent of school days in a given year, or about 18 days, affects the educational outcomes of millions of students. In order to inspire parents of 5th through 8th graders to recognize the crucial role regular attendance, even in the early years, plays in high school graduation, the U.S. Army and the Ad Council are unveiling a new series of public service advertisements (PSAs) created pro bono by advertising agency Publicis Kaplan Thaler.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58503-ad-council-boostup-high-school-dropout-prevention
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
There is a growing body of evidence linking yogurt consumption to improved health, and additional research to identify the scientific link between yogurt and potential health benefits, is underway scientists say. International nutrition experts gathered at the First Global Summit on the Health Effects of Yogurt in Boston on April 24, 2013 to present the current state of the science on the health effects of yogurt and identify research gaps that need to be addressed within the scientific community.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61206-american-society-nutrition-health-effects-yogurt-weight-chronic-disease
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
Would you like to learn more about Fibromyalgia pain? This video explains why those with Fibromyalgia have chronic pain.
Website: http://fibromyalgiainfonow.com/
Every Wednesday night on Fuse TV is a full-scale HIP HOP INVASION. Snoop Dogg comes to Fuse TV for an EXCLUSIVE interview w/ Toure to talk about his new album, Malice in Wonderland. Watch it @8pm/7C, encore @12am/11C http://fuse.tv/hiphopinvasion
Every Wednesday night on Fuse TV is a full-scale HIP HOP INVASION.
THIS WEDNESDAY: Snoop Dogg comes to Fuse TV for an EXCLUSIVE interview w/ Toure to talk about his new album, Malice in Wonderland. Watch it @8pm/7C, encore @12am/11C http://fuse.tv/hiphopinvasion
Today Walgreens (NYSE, NASDAQ: WAG), announced the Walgreens Way to Well Health Tour with AARP, a program dedicated to providing free prevention and early detection health services to some of the nation’s most underserved communities. Now through December 2012, the tour will provide free tests, assessments, education and consulting services to communities located predominantly in cities with the highest prevalence for leading diseases, and highest uninsured and unemployed populations.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54970-walgreens-way-to-well-health-tour-with-aarp
The CVS Caremark Charitable Trust, a private foundation created by CVS Caremark Corporation (NYSE: CVS) today announced the recipients of the “Innovations in Community Health” grants, which have been awarded to community health centers nationwide through a partnership with the National Association of Community Health Centers (NACHC). The grants will help community health centers increase access to quality health care and produce better health outcomes while reducing costs for patients and healthcare systems.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61405-cvs-caremark-charitable-trust-awards-21-innovations-in-community-health
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
